Floatz logo

Zilovertamab Vedotin

HER2-negative Breast Cancer

VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)antibody_drug_conjugatePhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

192 Active assets in the HER2-negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Palbociclib
Helwan University
Phase 2BBB
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2BBB
Atezolizumab
TransThera Sciences (Nanjing), Inc.
Phase 2BB
Inno-206
Roswell Park Cancer Institute
Phase 3BB

View all 50 →

Same molecule, other indications

Zilovertamab Vedotin is also rated in:

diffuse large B-cell lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
Richter transformationDormant
B
Indicative ·
60 / 100
View asset →
relapsed/refractory diffuse large B-cell lymphomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →